AspenBio Pharma’s AppyScore Test to conclude by March 31 (NASDAQ:APPY)
On February 9, 2010, AspenBio Pharma, Inc. (NASDAQ:APPY), which is a growing bio science company that develops innovative tests and drugs for the betterment of mankind,
Continue reading...Second Interim Results from Phase 3 trial expected by March 31 (NASDAQ:ARIA)
23 March 2010
Oral ridaforolimus is a drug that has been developed and manufactured by ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA). This drug can be used to treat patients who are suffering from “metastatic soft-tissue and bone sarcomasâ€.
Continue reading...Enrolling of Phase 2(b) participants expected on March 31 (Nasdaq:ALNY)
23 March 2010
Comments Off
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY) is a biopharmaceutical company that specializes in providing RNA-based treatment. It has a number of innovative products under its pipeline, and the number is increasing with each passing year.
Continue reading...Results from Oral Interferon’s Phase 2 trial expected by March 31 (OTCBB:AMAR)
23 March 2010
Comments Off
Oral interferon is a drug that has been discovered and developed by Amarillo Biosciences, Inc. (OTCBB:AMAR). According to the company, the drug can be used to cure people who have been infected with the influenza virus – more commonly known as just “fluâ€.
Continue reading...Preclinical study results of Cobalamin expected by March 31, 2010 (OTCBB:ACCP)
23 March 2010
Comments Off
Cobalaminâ„¢ is a drug delivery system that has been developed and manufactured by Access Pharmaceuticals, Inc. (OTCBB:ACCP).
Continue reading...Action date of XIFAXAN® expected on March 24 (Nasdaq:SLXP)
23 March 2010
Comments Off
On August 24, 2009, Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) disclosed that the FDA had found that the new drug application (NDA) – that was submitted for the company’s recently developed rifaximin tablets 550 mg (called XIFAXAN®)– contained all the information that would allow it to make a thorough review on the drug.
Continue reading...Results from LightTouch trials expected to be disclosed on March 24-27 meeting (PINK:GTHP), (OTC:GTHP)
23 March 2010
Comments Off
LightTouchâ„¢ is a non-invasive medical device that can detect cervical cancer. The device has been developed by Guided Therapeutics, Inc. (PINK and OTC:GTHP.PK). This device is capable of detecting cervical cancer in its early stages without causing any pain to the patient.
Continue reading...ODAC meeting with ChemGenex expected on March 22 (ASX:CXS) (Nasdaq:CXSPY)
23 March 2010
Comments Off
OMAPROâ„¢ (omacetaxine mepesuccinate) is a drug developed and manufactured by ChemGenex Pharmaceuticals Limited (ASX: CXS).
Continue reading...AstraZeneca’s Esomeprazole PDUFA Date Set For March (NYSE:AZN)
15 March 2010
Comments Off
A drug containing low aspirin and esomeprazole magnesium has been developed by AstraZeneca (NYSE:AZN), a major pharmaceutical company in the United States, over the last few years. Now the company is planning to bring thris drug into the market.
Continue reading...PDUFA date of APF530 expected next week (Nasdaq:APPA)
11 March 2010
Comments Off
APF530 is a drug that has been developed by A.P. Pharma Inc. (Nasdaq:APPA) using its “Biochronomerâ„¢ polymer-based drug delivery technologyâ€.
Continue reading...
23 March 2010
Comments Off